Raymond James & Associates Adamis Pharmaceuticals Corp Transaction History

Raymond James & Associates

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 08, 2022	SELL	$0.57 - $1.23 $9,260 - $19,982	-16,246 Closed	0 $0
Q3 2021 Nov 02, 2021	BUY	$0.92 - $1.18 $4,266 - $5,472	4,638 Added 39.96%	16,246 $16,000
Q2 2021 Aug 11, 2021	BUY	$0.66 - $1.23 $7,661 - $14,277	11,608 New	11,608 $13,000
Q4 2019 Feb 12, 2020	SELL	$0.51 - $1.26 $32,716 - $80,829	-64,150 Closed	0 $0
Q3 2019 Nov 07, 2019	BUY	$0.7 - $1.46 $11,550 - $24,090	16,500 Added 34.63%	64,150 $45,000
Q2 2019 Aug 06, 2019	BUY	$1.26 - $2.23 $1,890 - $3,345	1,500 Added 3.25%	47,650 $62,000
Q1 2019 May 06, 2019	SELL	$2.02 - $3.22 $6,960 - $11,096	-3,446 Reduced 6.95%	46,150 $97,000
Q4 2018 Feb 11, 2019	BUY	$2.1 - $3.21 $37,590 - $57,459	17,900 Added 56.47%	49,596 $112,000
Q3 2018 Nov 14, 2018	BUY	$2.25 - $4.8 $71,316 - $152,140	31,696 New	31,696 $111,000
Q1 2018 May 14, 2018	SELL	$2.55 - $4.85 $27,412 - $52,137	-10,750 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$3.5 - $5.65 $18,725 - $30,227	-5,350 Reduced 33.23%	10,750 $47,000
Q3 2017 Nov 13, 2017	BUY	$4.5 - $5.65 $24,075 - $30,227	5,350 Added 49.77%	16,100 $84,000
Q2 2017 Aug 14, 2017	BUY	N/A	10,750	10,750 $56,000

Ticker ADMP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 149,983,008
Market Cap $73.5M
Description
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emerg...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.